• Seattle Genetics Inc., of Bothell, Wash., and Millennium: The Takeda Oncology Co., of Cambridge, Mass., completed patient enrollment in a Phase III trial of Adcetris (brentuximab vedotin) in post-transplant Hodgkin lymphoma (HL).